We serve Chemical Name:(4-benzylpiperazin-1-yl)-piperidin-4-ylmethanone,dihydrochloride CAS:1185013-84-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4-benzylpiperazin-1-yl)-piperidin-4-ylmethanone,dihydrochloride
CAS.NO:1185013-84-6
Synonyms:(4-Benzylpiperazin-1-yl)piperidin-4-yl-methanone dihydrochloride
Molecular Formula:C17H27Cl2N3O
Molecular Weight:360.32200
HS Code:2933599090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:35.58000
Exact Mass:359.15300
LogP:3.13900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (4-Benzylpiperazin-1-yl)piperidin-4-yl-methanone dihydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-Benzylpiperazin-1-yl)piperidin-4-yl-methanone dihydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-Benzylpiperazin-1-yl)piperidin-4-yl-methanone dihydrochloride Use and application,(4-Benzylpiperazin-1-yl)piperidin-4-yl-methanone dihydrochloride technical grade,usp/ep/jp grade.
Related News: “It’s truly an important scientific issue and important public health issue and FDA is actively exploring all regulatory options for providing access to additional doses of authorized vaccines in situations where data suggests the benefits would outweigh the risks,” Fink said. (S)-2-(2-Benzoyl-phenylamino)-3-(4-[2-(10,11-dihydro-dibenzo[b,f]azepin-5-yl)-ethoxy]-phenyl)-propionic acid methyl ester manufacturers Franco Stevanato, Giovanni’s 48-year-old grandson and the company’s executive chairman since stepping down as CEO in February, had his grandfather’s vision in mind when he virtually rang the opening bell on Wall Street on Tuesday. (2-amino-thiazol-4-yl)-(Z)-butoxyimino-acetic acid suppliers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. N-(4-methoxybenzyl)-5-amino-1-pent-2-ynoic tert-butyl ester vendor & factory.
